Moreover, gain-of-function mutations in RAS rank among the most frequently observed genetic lesions in human cancers (1, 5), and the KRAS isoform alone is mutated in 9% of cancer cases, with high frequency in pancreatic ductal adenocarcinoma (72%), genomically stable colorectal cancer (69%), and non–small cell lung cancer (33%) (4). The gene discussed is KRAS; the disease is cancer.